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Abstract
The first syntheses of 13,14-didehydroxyisogarcinol (6) and garcimultiflorone A (5) stereoisomers 
are reported in six steps from a commercially available phloroglucinol. Lewis acid-controlled, 
diastereoselective cationic oxycyclizations enabled asymmetric syntheses of (−)-6-epi-6 and 
(+)-30-epi-6. A similar strategy enabled production of the meso-dervied isomers (±)-6,30-epi-6 
and (±)-6,30-epi-5. Finally, a convenient strategy for gram scale synthesis was developed utilizing 
diastereomer separation at a later stage in the synthesis that minimized the number of necessary 
synthetic operations to access all possible stereoisomers.
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1. INTRODUCTION
For the past 15 years, the synthetic and biological communities have been interested in 
polyprenylated polycyclic acylphloroglucinols (PPAPs) as natural product targets and 
starting points for SAR studies due to their diverse bioactivity profiles (Figure 1A). Not 
surprisingly, with minor structural differences leading to significant variation in bioactivity, 
PPAP natural products and their analogs are considered high priority targets for isolation, 
chemical synthesis, and biological studies.1,2 The natural products isogarcinol (1) and 
garcinol (2) have gained significant attention in recent years and are lead compounds for 
several clinical indications.3,4 The importance of synthesizing diverse analogs of both 
garcinol and isogarcinol to probe their biological activities was recently emphasized.5,6
Isogarcinol’s dehydroxy isomer 13,14-didehydroxyisogarcinol (6) and the type A variant 
garcimultiflorone A (5) were isolated in 2009 from the fruits of Garcinia multiflora in South 
China and were reported to possess anti-inflammatory activity by inhibiting superoxide and 
elastase enzymes released from human neutrophils (Figure 1A).7 Apart from this single 
report, however, no additional information on the biological activities of natural products 5 
and 6 exist further emphasizing the need for an efficient and scalable synthetic route to this 
class. Although studies have reported the importance of 13,14-hydroxyls with regard to 
isogarcinol’s histone acetyltransferase (HAT) inhibition and radical-scavenging 
abilities,2a,6,8c,d,11e biological data on analogs that lack the hydroxyl functionalities (e.g., 5 
and 6) are limited.7 Given that we were able to procure natural products 5 and 6 from the 
isolation team led by Chen and co-workers,7 our goal was to develop a strategy for accessing 
non-natural diastereomers of 5 and/or 6 for further biological studies (Figure 1B).
We were intrigued by the marked similarity of 13,14-didehydroxyisogarcinol (6) to 
isogarcinol (1), a compound that has activity in numerous therapeutic indications including 
leukemia,8a,i colon cancer,8b,i HIV,8c,d brain tumors (medulloblastoma),8e antioxidant,8f 
antimicrobial,8f transplantation rejection and autoimmune diseases,8g,h,l collagen-induced 
and rheumatoid arthritis,8j breast cancer,8k and Parkinson’s disease.8m Interestingly, 
isogarcinol (1) is also available for human consumption in mangosteen drinks and capsules 
as a remedy for arthritis.9 Only one total synthesis of 1 has been reported since its isolation 
in 1980, an elegant strategy accomplished in 15 steps by Pleitker and co-workers.10,11a The 
compound has been isolated from numerous sources,11 and a large scale extraction 
procedure was developed for its procurement.11g
Stereoisomers of 5 and 6 have not yet been isolated in nature, which further emphasizes the 
need for a synthetic platform to access such candidates (Figure 1B),8i,23 especially given the 
diverse bioactivities of isogarcinol’s closely related congeners, specifically garcinol (2),11a 
cycloxanthochymol,12b,d 30-epi-cambogin A (3),12a,c,f,h and 7-epi-isogarcinol (4).12b,d,e,g 
Herein, we describe asymmetric syntheses of (+)-30-epi-6 and (−)-6-epi-6 in six steps from 
commercially available phloroglucinol 12 utilizing Lewis acid-dependent diastereoselective 
oxycyclizations (Figure 2). Using a similar strategy, we also demonstrate the syntheses of 
meso-derived isomers (±)-6,30-epi-6 and (±)-6,30-epi-5 (cf. Scheme 2B). Finally, a 
convenient strategy for the large scale synthesis of these enantiopure and racemic 
stereoisomers is demonstrated.
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Retrosynthetic analysis of enantiopure isomers (−)-6-epi-6 and (+)-30-epi-6 from 
commercially available phloroglucinol 12 is shown in Figure 2. Isomers (−)-6-epi-6 and 
(+)-30-epi-6 may be derived from cross metathesis and cationic cyclization of precursors 
(−)-7 and (+)-21, respectively. Vinylic allylation of the unsubstituted precursors (−)-8 and 
(+)-13 should enable access to respective pyranodienones (−)-7 and (+)-21. We envisioned 
that diastereoselective, cationic oxycyclization mediated through Lewis-acid chelation of 
(+)-(S,S)-9A may furnish (−)-8 and/or (+)-13 in reasonable diastereoselectivity. 
Regioselective bis-alkylation of acylphloroglucinol 10 using the triflate derived from alcohol 
(−)-(R)-11 may provide dearomatized adduct (+)-(S,S)-9A.13 Finally, our laboratory has 
previously shown that compound 10 is conveniently derived from the commercially 
available monomethylphloroglucinol 12 via Friedel–Crafts acylation.13
2. RESULTS AND DISCUSSION
At the outset of our investigation, racemic alcohol (±)-11 was prepared in the same manner 
previously described by our group in a single step from commercially available starting 
materials.13 Pleasingly, triflation of (±)-11 was followed by regioselective bis-alkylation of 
acylphloroglucinol 10 in the presence of LiHMDS providing the dearomatized enols (±)-9A, 
(meso)-9B, and (meso)-9C in 53% yield (Scheme 1). The (R) and (S) alkyl substituents of 
(meso)-9B and (meso)-9C create a mirror plane of symmetry in each structure rendering 
them achiral/meso (Figure 3). Alternatively, compound (+)-(S,S)-9A could be produced as a 
single, enantiopure diastereomer via bis-alkylation of acylphloroglucinol 10 utilizing the 
enantioenriched triflate derived from alcohol (−)-(R)-11 (Scheme 1). A multigram scale 
synthesis of alcohol (−)-(R)-11 was achieved from a modified and improved 3-step 
protocol.14 Because of their tendency to form calcium salts on silica gel,13 enol (+)-(S,S)-9A 
and racemic variants (±)-9A, (meso)-9B, and (meso)-9C were conveniently purified by 
potassium salt formation without the need for column chromatography.14 The structure of 
(meso)-9C was confirmed by X-ray crystal structure analysis.14
We next evaluated the possibility for diastereoselective oxycyclization of (+)-(S,S)-9A to 
provide the enantiopure pyranodienones (−)-8 and (+)-13 (Table 1). The diastereoselectivity 
in this case would result if the two 1,1-disubstituted alkenes of (+)-(S,S)-9A are protonated 
at different rates. A number of acidic conditions were evaluated for cyclization including 
HCl in CH2Cl2, which provided (−)-8 and (+)-13 in 1:1.1 d.r. (Table 1, entry 1). After 
considerable experimentation, we discovered that binary acid combinations15 of LiBr with 
either chiral or achiral phosphoric acids provided high yields of (−)-18 and (+)-13 in roughly 
1:2 d.r. in favor of (+)-13 (Table 1, entries 2–8). In the absence of LiBr, the reaction did not 
proceed as the acidity of the phosphoric acid was presumably enhanced through lithium 
coordination (Table 1, entry 10). Because both chiral (14–17) and achiral phosphoric acids 
(18 and 19) provided similar outcomes with LiBr (Table 1, entries 2–8), we anticipated that 
the observed diastereoselectivity may be the result of Lewis acid coordination to enol (+)-
(S,S)-9A which was supported by the fact that LiBr alone favored (+)-13 in 1:1.6 d.r. (Table 
1, entry 11).
As it is known that Lewis acid coordination to Brønsted acid restricts the orientational 
flexibility of the proton,16,17 metal coordination to the β-keto enol functionality of (+)-
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(S,S)-9A may restrict the orientation of its enol proton in addition to making it more acidic 
and prone to react with the proximal 1,1-disubstituted olefin.16 Indeed, we discovered that 
stronger Lewis acids (e.g., SbCl5 and SnCl4) improved the overall diastereoselectivity. For 
example, evaluation of the Lewis acid-assisted Brønsted acid (LBA) system developed by 
Corey and co-workers,19 SbCl5 with 2,2′-dichloro-(S)-BINOL (S)-17 in CH2Cl2 at −78 °C, 
led to the production of (−)-8 in 18% yield and 9:1 d.r. (Table 1, entry 9).
The effect of chelation on diastereoselectivity was also evaluated by saturating the open 
coordination sites on SnCl4 with (±)-14 to generate the corresponding LBA and prevent 
substrate chelation.14,18 In this case, reaction was not observed until the temperature reached 
50 °C providing clean formation of products (−)-8 and (+)-13 in 58% yield and 1:1.1 d.r 
(Table 1, entry 13).
After screening an array of Lewis acids with variations in size and coordination ability along 
with different phosphoric acid promoters, optimized conditions for diastereoselective 
cyclization to (−)-8 or (+)-13 were identified (Table 2). The combination of SnCl4 with the 
inexpensive, achiral diphenylphosphoric acid 18 ($3.18/gram) required lower reaction times 
and provided a cost-effective approach for the production of (−)-8 (47%, 10:1 d.r., Table 2, 
entry 4). Interestingly, the opposite selectivity for cyclization was highly favored only in the 
case of BF3-OEt2 and p-TsOH which provided (+)-13 in 42% yield and 1:5 d.r. (Table 2, 
entry 6).
It has been reported that SnCl4 and BF3-OEt2 can bind in a bidentate fashion to β-keto enol 
substrates resulting in the formation of hexacoordinate Sn- and tetrahedral BF2-
complexes.16a,20,21 We hypothesized that the observed diastereoselectivity may be governed 
by an intramolecular protonation event following complex formation wherein the proximal 
olefin approach is perpendicular to the acidic enol proton.16a,17e As SnCl4 alone provided 
(−)-8 in 7:1 d.r. and 36% yield (Table 1, entry 12), we simplified our transition state analysis 
by examining bidentate complexes without Brønsted acid ligand (Figure 4A,B). Indeed, 
analysis of transition states indicated that complex SnCl4-9A-TS1 appears to favor 
cyclization to (−)-8 by an energy difference of 5.3 kcal/mol in comparison with transition 
state SnCl4-9A-TS2 leading to (+)-13 (Figure 4A). This discrimination may be explained in 
part by improved stabilization of SnCl4-9A-TS1 via coordination of the two chlorine ligands 
to the acidic enol proton and to the emerging carbocation.14,17a,24 In contrast, complex 
BF2-9A-TS2 favors the formation of (+)-13 by an energy difference of 3.8 kcal/mol relative 
to BF2-9A-TS1 leading to (−)-8 which correlates with our experimental results (Figure 4B). 
To the best of our knowledge, this represents the first example of a SnCl4- or BF3-OEt2-
phosphoric acid LBA system and the first Lewis acid-controlled diastereoselective 
oxycyclization of dearomatized acylphloroglucinols.
With optimized methods for accessing either (−)-8 or (+)-13 from (+)-(S,S)-9A (Scheme 
2A), oxycyclization of meso-9B and meso-9C was also achieved in short reaction times and 
reasonable yield with use of LiBr and diphenyl phosphate (Scheme 2B). Vinylic allylation of 
pyranodienones (−)-8, (+)-13, 23, and 26 proceeded smoothly utilizing lithium 2-
thienylcyanocuprate to provide the cyclization precursors (−)-7, (+)-21, 24, and 27 
respectively in good yields (Scheme 2A,B).22
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In our efforts to cyclize compound (−)-7 to the PPAP core (−)-20, we observed undesired 
conversion to product 25 in dry TFA. However, we discovered that isomerization could be 
completely avoided in the presence of water allowing for efficient cyclization to cycloadduct 
(−)-20 with 1:1 H2O/TFA (Scheme 2A). Compound 24 seamlessly cyclized at 60 °C after 
1.5 h in dry TFA to its respective [3.3.1]-bicyclic core 25 in good yield (Scheme 2B). The 
relative stereochemical assignments of compound 25 were determined by detailed NOE 
studies and were later confirmed by X-ray crystal structure analysis (Scheme 3B).14
The cyclization of compound (+)-21 to (+)-22 proved more challenging, which may be due 
to unfavorable steric interactions shown in transition state 29 (Figure 5). The axially oriented 
allyl group at C6 likely experiences destabilizing interactions with the proximal benzoyl or 
cyclohexadienone functionalities disfavoring cyclization to product (+)-22.13 In contrast, the 
C6 allyl group in transition state 30 is equatorially oriented and avoids steric influences that 
would deter cyclization to the desired stereoisomer 25.
After considerable experimentation, we discovered that the formation of the C-cyclization 
adduct (+)-22 could only be achieved in the presence of water, where 1% H2O/TFA provided 
an optimized yield of 14% (Scheme 2A) along with 69% of byproduct (+)-31 (cf. Scheme 
3A). The relative stereochemical assignment of compound 22 was determined by X-ray 
crystal structure analysis (Scheme 3A).14 Formation of the undesired O-cyclization product 
(+)-31 may result from hydrolysis of methyl enol ether (+)-21 in H2O/TFA as further 
increasing the water content provided higher yields of byproduct (+)-31. It is also notable 
that compound (+)-21 did not cyclize in dry TFA even after stirring for 24 h at room 
temperature. Furthermore, in the presence of 1:1 H2O/TFA, exclusive formation of (+)-31 
was observed.
Pyranodienone 27, shown in Scheme 2B, proved unsuitable for cyclization to its 
corresponding type B PPAP core which was likely impeded by undesired steric interactions 
in the transition state analogous to those noted in Figure 5. Surprisingly, we discovered that 
1:1 H2O/TFA induced unexpected cyclization at C2 of compound 27 cleanly furnishing type 
A PPAP core 28 in 79% yield (Scheme 2B). As one possibility, the cyclization of 27 may 
proceed through a cationic rearrangement wherein acid-induced pyran opening leads to 
cyclization at C2 and a formal 1,3-shift25 followed by an oxycyclization/demethylation 
sequence. Pleasingly, olefin metathesis proceeded efficiently for all stereoisomers providing 
type B PPAPs (−)-6-epi-6, (+)-30-epi-6, (±)-6,30-epi-6, and type A PPAP (±)-6,30-epi-5 in 
excellent yields (Scheme 2A,B).
Finally, a convenient strategy for large scale production of all stereoisomers was developed 
by enabling diastereomer separation at a later stage in the synthesis which minimized the 
number of necessary synthetic operations (Scheme 3). A scalable strategy for the synthesis 
of enantiopure bicyclo[3.3.1]-nonanes (−)-20 and (+)-22 is demonstrated in Scheme 3A. 
Gram scale oxycyclization of enol (+)-(S,S)-9A with LiBr and diphenyl phosphate 18 
provided (−)-8 and (+)-13 in 79% yield (1:1.8 d.r. as determined by 1H NMR analysis). 
Furthermore, phosphoric acid 18 could be recovered after workup.14 Vinylic allylation 
served as the most convenient stage for diastereomer separation where column 
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chromatography was sufficient to provide ample quantities of products (+)-21 and (−)-7 for 
subsequent cyclization.
A convenient strategy for gram scale synthesis of racemic stereoisomers 20, 22, 25, and 28 
is shown in Scheme 3B. In comparison, their synthesis would require a total of 13 steps (4 
steps for each isomer) by the strategy presented in Schemes 1 and 2. Hence, our modified 
gram scale sequence in Scheme 3B accomplishes the same goal in 9 fewer steps providing a 
superior alternative for the synthesis of (±)-6-epi-6, (±)-30-epi-6, (±)-6,30-epi-6, and (±)-6-
epi-5. To produce modest yields of each diastereomer in the final cyclization step of Scheme 
3B, it was necessary to use 10% H2O/TFA as 1% H2O/TFA would improve the yield of 
stereoisomer 22 but minimize formation of 28 (Scheme 3B). Moreover, substantially raising 
the water content employing 1:1 H2O/TFA as solvent would prevent synthesis of product 22 
and maximize formation of the type A PPAP core 28. This gram scale strategy demonstrated 
that all stereoisomers 20, 22, 25, and 28 could be achieved in only 4 synthetic operations 
from acylphloroglucinol 10 in a time frame of 72 h (Scheme 3B).14 It should be noted that 
compounds 20 and 25 were isolated as a mixture by column chromatography and could be 
further separated for characterization and biological evaluation by preparative TLC.14
3. CONCLUSION
In conclusion, all non-natural diastereomers of 13,14-didehydroxyisogarcinol (6) and one 
diastereomer of garcimultiflorone A (5) were synthesized for the first time by an efficient six 
step strategy from the commercially available phloroglucinol 12 using regioselective bis-
alkylation, Lewis acid-controlled oxycyclization, and cationic C-cyclization as key steps. 
Type B stereoisomers (−)-6-epi-6, (+)-30-epi-6, and (±)-6,30-epi-6 were obtained in up to 
22%, 2%, and 16% respective overall yields from acylphloroglucinol 10. Notably, our 
synthesis also provided the type A PPAP (±)-6,30-epi-garcimultiflorone A ((±)-6,30-epi-5) 
in 8.4% overall yield from 10. Moreover, diastereoselective oxycyclization of (+)-(S,S)-9A 
utilized novel SnCl4 and BF3-OEt2 LBA systems to induce stereoselective, intramolecular 
protonation resulting in selective formation of either pyranodienone (−)-8 or (+)-13. Finally, 
a gram scale strategy was developed to allow for production of ample quantities of each 
isomer in a single synthetic sequence which minimized step count and purification events. 
Notably, a synthesis of bicyclo[3.3.1]nonanes (−)-20 and (+)-22 was achieved without the 
need for preparative TLC and the production of stereoisomers 20, 22, 25, and 28 could be 
accomplished in only 4 synthetic operations from acylphloroglucinol 10. Further studies on 
the chemistry and biology of garcimultiflorone A (5), 13,14-didehydroxyisogarcinol (6), and 
their stereoisomers are in progress and will be reported in future publications.
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Figure 1. 
Representative PPAP natural products and diastereomers of 13,14-didehydroxyisogarcinol 
and garcimultiflorone A obtained in this work.
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Figure 2. 
Retrosynthetic Analysis for (−)-6-epi-6 and (+)-30-epi-6.
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Figure 3. 
Symmetry of meso isomers 9B and 9C represented by 3D models.
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Figure 4. 
(A) Relative transition state energies for intramolecular protonation of SnCl4-9A. (B) 
Relative transition state energies for intramolecular protonation of BF2-9A.
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Figure 5. 
Comparison of transition state models for cyclization to (+)-22 and 25.
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Scheme 1. 
Regioselective bis-Alkylation of Acylphloroglucinol 10: Racemic and Enantioenriched 
Variants
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Scheme 2. 
Asymmetric Syntheses of (−)-6-epi-6 and (+)-30-epi-6 and Racemic Syntheses of (±)-6,30-
epi-6 and (±)-6,30-epi-5
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Scheme 3. 
Scalable Strategy for Production of (−)-20 and (+)-22 and Gram Scale Synthesis of Racemic 
Stereoisomers 20, 22, 25, and 28 in a Single Synthetic Sequence
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